Car Buying | Migraine | Handicraft | Domain Availability | Blog2Read | Hrithik Roshan | Digital Movies |


Explore the categories so you can find more about your search.

Categorie > Clinical Trials / Drug Trials

Treatment Of Portal Hypertensive Pulmonary Lesions Induced By Schistosomiasis

Categorie : Clinical Trials / Drug Trials
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes ...

read more To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes read more Sat Mar 2010 Sat Mar 2010

Transcendental Meditation Activates Default Mode Network, The Brain's Natural Ground State

Categorie : Clinical Trials / Drug Trials
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique... ...

read more A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural read more Sat Mar 2010 Sat Mar 2010

Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis

Categorie : Clinical Trials / Drug Trials
Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scien ...

read more Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scien read more Sat Mar 2010 Sat Mar 2010

ISIS Initiates Phase 1 Clinical Trial Of ISIS-SOD1Rx In Patients With ALS

Categorie : Clinical Trials / Drug Trials
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are caused b ...

read more Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are caused b read more Sat Mar 2010 Sat Mar 2010

COPPERTONE(R) Solar Research Center Unveils Studies On Efficacy Of Topical Antioxidants In Sunscreens At 2010 Annual Meeting

Categorie : Clinical Trials / Drug Trials
Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc., the makers of COPPERTONE®, announced at the 2010 Annual Meeting of the American Academy of Dermatology the results of studies demonstrating the efficacy of topical antioxidants in broad spectrum sunscr ...

read more Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc., the makers of COPPERTONE®, announced at the 2010 Annual Meeting of the American Academy of Dermatology the results of studies demonstrating the efficacy of topical antioxidants in broad spectrum sunscr read more Sat Mar 2010 Sat Mar 2010

Poniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study Of Picoplatin In Metastatic Prostate Cancer

Categorie : Clinical Trials / Drug Trials
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castr ...

read more Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castr read more Sat Mar 2010 Sat Mar 2010

Ocular Shingles Linked To Increased Risk Of Stroke

Categorie : Clinical Trials / Drug Trials
Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology. For the study, researchers identified 658 people diagnosed with ocular s ...

read more Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology. For the study, researchers identified 658 people diagnosed with ocular s read more Fri Mar 2010 Fri Mar 2010

Parkinson's Disease Makes It Harder To Figure Out How Other People Feel

Categorie : Clinical Trials / Drug Trials
Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association... ...

read more Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association... read more Fri Mar 2010 Fri Mar 2010

Second Dose Of Gene Therapy For Inherited Blindness Proves Safe In Animal Study

Categorie : Clinical Trials / Drug Trials
Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle... ...

read more Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle... read more Fri Mar 2010 Fri Mar 2010

Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival In Patients With Metastatic Castrate-Resistant Prostate Cancer

Categorie : Clinical Trials / Drug Trials
Dendreon Corporation (Nasdaq: DNDN) announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate can ...

read more Dendreon Corporation (Nasdaq: DNDN) announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE® (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate can read more Fri Mar 2010 Fri Mar 2010

Evidence-Based Treatment For Childhood Epilepsy

Categorie : Clinical Trials / Drug Trials
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy the most common form of epilepsy in kids has established an evidence-based approach for initial drug therapy... ...

read more The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy the most common form of epilepsy in kids has established an evidence-based approach for initial drug therapy... read more Fri Mar 2010 Fri Mar 2010

Pneumococcal Vaccine Offers Protection To HIV-infected African Adults In Clinical Trial

Categorie : Clinical Trials / Drug Trials
A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. The trials, conducted in Malawi and funded by the Wellcome Trust, studied the efficacy of a vaccine against infectio ...

read more A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. The trials, conducted in Malawi and funded by the Wellcome Trust, studied the efficacy of a vaccine against infectio read more Fri Mar 2010 Fri Mar 2010

Evidence-Based Care For Childhood Epilepsy Follows Comparative Effectiveness Trial

Categorie : Clinical Trials / Drug Trials
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy... ...

read more The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy - the most common form of epilepsy in kids - has established an evidence-based approach for initial drug therapy... read more Fri Mar 2010 Fri Mar 2010

FDA Provides 510k Clearance For BARRX Medical's HALO90 Ablation Catheter For The Treatment Of Radiation Proctitis And Gastric Antral Vascular Ectasia

Categorie : Clinical Trials / Drug Trials
BARRX Medical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its HALO90 Ablation Catheter for the treatment of Radiation Proctitis (RP) and Gastric Antral Vascular Ectasia (GAVE). Both conditions are diseases of the gastrointestinal ...

read more BARRX Medical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its HALO90 Ablation Catheter for the treatment of Radiation Proctitis (RP) and Gastric Antral Vascular Ectasia (GAVE). Both conditions are diseases of the gastrointestinal read more Fri Mar 2010 Fri Mar 2010

OmniComm Introduces TrialOneTM - An Integrated Suite Of Web Based Solutions For Phase I Clinic Automation And Management

Categorie : Clinical Trials / Drug Trials
OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web-based solution designed to automate the Phase I Clinical Trial Process... ...

read more OmniComm Systems, Inc. (OTCBB: OMCM), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web-based solution designed to automate the Phase I Clinical Trial Process... read more Fri Mar 2010 Fri Mar 2010

Pycnogenol Lowers Elevated Urinary Protein Levels And Improves Blood Flow To The Kidneys

Categorie : Clinical Trials / Drug Trials
An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults... ...

read more An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults... read more Fri Mar 2010 Fri Mar 2010

Transplant Drug Preserves Kidneys, Avoids Toxicity

Categorie : Clinical Trials / Drug Trials
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show. The results are published in the March issue of the Am ...

read more The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show. The results are published in the March issue of the Am read more Fri Mar 2010 Fri Mar 2010

Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol To FDA

Categorie : Clinical Trials / Drug Trials
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). "The progressi ...

read more Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). read more Fri Mar 2010 Fri Mar 2010

Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority

Categorie : Clinical Trials / Drug Trials
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and ...

read more Cell Therapeutics, Inc. ( read more Fri Mar 2010 Fri Mar 2010

ReShape Medical Announces Initiation Of U.S. Clinical Study For Weight Loss

Categorie : Clinical Trials / Drug Trials
ReShape Medical™, Inc. announced that it has initiated a U.S. Investigational Device Exemption (IDE) clinical study to assess the safety and effectiveness of its non-surgical, dual-balloon device for weight loss. The ReShape Balloons are designed to be a treatment for the millions who want suppor ...

read more ReShape Medical™, Inc. announced that it has initiated a U.S. Investigational Device Exemption (IDE) clinical study to assess the safety and effectiveness of its non-surgical, dual-balloon device for weight loss. The ReShape Balloons are designed to be a treatment for the millions who want suppor read more Fri Mar 2010 Fri Mar 2010

1 | 2 | 3 | 4 next >>>